Announcements and Notices - [Other - Business Update]

Keymed Biosciences Inc. operates a biotechnology company. The Company focus on the in-house discovery and development of innovative biological therapies. Keymed Biosciences provides services in China.

Voluntary Announcement
Exclusive License Agreement For Cm336

Financial Statements/ESG Information - [Interim/Half-Year Report]

2024 Interim Report

Announcements and Notices - [Inside Information]

Inside Information Announcement
Stapokibart Was Granted Marketing Approval From
National Medical Products Administration For The
Treatment Of Moderate-To-Severe
Atopic Dermatitis In Adults

Announcements and Notices - [Interim Results]

Interim Results Announcement
For The Six Months Ended June 30, 2024

Announcements and Notices - [Date of Board Meeting]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Keymed Biosciences (2162 HK)

Voluntary Announcement Exclusive License Agreement For Cm336

2024 Interim Report

Inside Information Announcement Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-To-Severe Atopic Dermatitis In Adults

Interim Results Announcement For The Six Months Ended June 30, 2024

Date Of Board Meeting

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)